ArticleBlood advances2018

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

James L Rubenstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.